Why the study?
Does a drug-eluting stent reduce target lesion revascularization and improve angiographic outcomes compared to a bare-metal stent in patients undergoing simultaneous implantation?
Does a drug-eluting stent reduce target lesion revascularization and improve angiographic outcomes compared to a bare-metal stent in patients undergoing simultaneous implantation?
Answers are grounded in this paper and cite their sources.
In patients undergoing hybrid stenting, drug-eluting stents provide superior angiographic outcomes and significantly lower rates of target lesion revascularization compared to bare-metal stents.
BACKGROUND: Simultaneous drug-eluting stent (DES) and bare-metal stent (BMS) implantation is occasionally employed in clinical practice, but its long-term clinical and angiographic outcome is not clear. HYPOTHESIS: We aimed to describe the long-term clinical outcome and the findings of clinically indicated coronary angiography in patients subjected to simultaneous DES and BMS implantation ("hybrid stenting"). METHODS: We identified 236 patients (mean age 62.9 ± 11.4 years, 76.7% men) who had undergone percutaneous coronary intervention with at least 1 DES and 1 BMS. At a median follow-up of 42 months (range, 6-89 months) available in 222 patients, 13 (5.9%) patients died from cardiac causes, 13 (5.9%) experienced nonfatal acute myocardial infarction, and 24 (10.8%) experienced unstable angina. Clinically indicated repeat coronary angiography was performed in 64 patients (28.8%). RESULTS: Thirty-one patients (14%) had target lesion revascularization (TLR). The DES demonstrated lower TLR rates (15.9% vs 36.9%, P = 0.002) and lower late loss (0.44 ± 0.5 mm vs 0.68 ± 0.7 mm, P = 0.009) compared with BMS. Use of DES was independently associated with lower risk for binary restenosis (hazard ratio [HR]: 0.41, 95% confidence interval [CI]: 0.19-0.89, P = 0.03) and TLR (HR: 0.26, 95% CI: 0.12-0.54, P<0.001). CONCLUSIONS: Although a hybrid stenting strategy demonstrates a reasonable long-term prognosis even in high-risk patients, DES have a better angiographic outcome compared with BMS under the influence of common patient-related restenosis risk factors.
No takes yet. Share an insight, caveat, or question.
Alexopoulos et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: